Related Experiment Video

Updated: Jun 2, 2026

Bio-layer Interferometry for Measuring Kinetics of Protein-protein Interactions and Allosteric Ligand Effects
13:57

Bio-layer Interferometry for Measuring Kinetics of Protein-protein Interactions and Allosteric Ligand Effects

Published on: February 18, 2014

Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance

Bing Luan1, Jian Zhao, Haiya Wu

  • 1Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, and Graduate School of the Chinese Academy of Sciences.

Nature
|January 6, 2009
PubMed

Insights

Beta-arrestin-2 deficiency worsens insulin resistance in type 2 diabetes. Restoring beta-arrestin-2 levels improves insulin sensitivity, offering new therapeutic targets for this metabolic disorder.

Area of Science:

  • Molecular biology
  • Endocrinology
  • Cell signaling

Background:

  • Insulin resistance is a key feature of type 2 diabetes, impairing insulin receptor signaling.
  • The phosphatidylinositol-3-OH kinase (PI(3)K)-Akt pathway is crucial for mediating insulin's metabolic actions.
  • Beta-arrestins are known regulators of G-protein-coupled receptor signaling specificity.

Purpose of the Study:

  • To investigate the role of beta-arrestin-2 in insulin resistance and type 2 diabetes.
  • To elucidate the molecular mechanisms by which beta-arrestin-2 influences insulin signaling.
  • To identify potential therapeutic targets for insulin resistance.

Main Methods:

  • Utilized diabetic mouse models to study beta-arrestin-2 levels and function.
  • Performed knockdown and administration experiments to assess the impact of beta-arrestin-2 on insulin sensitivity.
  • Investigated the formation of beta-arrestin-2 signaling complexes with insulin receptor, Akt, and Src.

Main Results:

  • Beta-arrestin-2 was found to be downregulated in diabetic mouse models.
  • Knockdown of beta-arrestin-2 exacerbated insulin resistance, while its administration improved insulin sensitivity.
  • Insulin stimulation promotes a beta-arrestin-2 complex that scaffolds Akt and Src to the insulin receptor.

Conclusions:

  • Loss or dysfunction of beta-arrestin-2 disrupts insulin signaling, contributing to insulin resistance and type 2 diabetes progression.
  • Beta-arrestin-2 plays a critical role in maintaining insulin sensitivity.
  • Findings suggest beta-arrestin-2 as a novel target for preventing and treating insulin resistance and type 2 diabetes.

More Related Videos

Real Time Measurements of Membrane Protein:Receptor Interactions Using Surface Plasmon Resonance (SPR)09:35

Real Time Measurements of Membrane Protein:Receptor Interactions Using Surface Plasmon Resonance (SPR)

Published on: November 29, 2014

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors10:28

A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors

Published on: August 17, 2019

Related Concept Videos

Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased ATP...
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
ATP Synthase: Structure01:18

ATP Synthase: Structure

ATP synthase or ATPase is among the most conserved proteins found in bacteria, mammals, and plants. This enzyme can catalyze a forward reaction in response to the electrochemical gradient, producing ATP from ADP and inorganic phosphate. ATP synthase can also work in a reverse direction by hydrolyzing ATP and generating an electrochemical gradient. Different forms of ATP synthases have evolved special features to meet the specific demands of the cell. Based on their specific feature, ATP...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...